HUMA Stock — Humacyte Inc.: Cash, EV, Pipeline

Share price

$0.59

Market cap

$162.7M

Cash

$79.9M

Enterprise value

$119.1M

Balance sheet

Cash	$79.9M
Debt	$36.3M
Net cash	$43.6M
Enterprise value	$119.1M
Basic shares	277.8M shares
Fully diluted shares	338.0M shares
Fully diluted market cap	$199.4M
Cash per share	$0.29

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading HUMA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Acellular Tissue Engineered Vessel (ATEV)	Phase 3	End Stage Renal Disease (ESRD)	—
Jan 12 - Feb 23	Acellular Tissue Engineered Vessel (Symvess)	Phase 3	Vascular Trauma; Arterial Injury; Arterial Bleeding	—
Oct 13 - Nov 24	Humacyte Coronary Tissue Engineered Vessel (CTEV)	Phase 2	Coronary Artery Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Symvess

Approved · Active Modality: regenerative medicine (bioengineered vessel)

Aliases acellular tissue engineered vessel, ATEV

Partnerships Fresenius Medical Care (agreement to sell, market and distribute 6mm ATEV for specified indications and markets, if approved); Kingdom of Saudi Arabia (commitment to purchase Symvess for clinical evaluation and outreach program)

Indications

extremity vascular trauma (Approved)

Status note Commercial product. ATEV assigned a priority designation by the Secretary of Defense under Public Law 115-92 (2018) to expedite FDA review for conditions facing military personnel.

ATEV (AV access program)

Phase 3 · Active Modality: regenerative medicine (bioengineered vessel)

Indications

arteriovenous access for hemodialysis (Phase 3)

Catalysts

— H2 2026

Status note Ongoing V007 and V012 Phase 3 trials in AV access for hemodialysis. V012: prospective randomized blinded trial, target 150 women, 113 enrolled, interim analysis planned on first 80 patients after one year of follow-up. Targeting patients at high risk of fistula failure/non-maturation.

BVP

Preclinical · Active Modality: regenerative medicine (bioengineered vessel)

Aliases biovascular pancreas

Partnerships Yale University (worldwide patent license, Aug 2019); Breakthrough T1D / JDRF (Industry Discovery and Development Partnership, Apr 2023, for preclinical development and testing)

Indications

type 1 diabetes (Preclinical)

Status note Biovascular pancreas designed to deliver insulin-producing islets using the ATEV as a means of treating type 1 diabetes.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Acellular Tissue Engineered Vessel (ATEV)
Lead indication	End Stage Renal Disease (ESRD)
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05908084	Phase 3	Active, not recruiting	Sponsor	HUMA	—	End Stage Renal Disease (ESRD)	—
NCT07762313	Phase 3	Not yet recruiting	Sponsor	HUMA	—	Vascular Trauma; Arterial Injury; Arterial Bleeding	—
NCT07730528	Phase 2	Not yet recruiting	Sponsor	HUMA	—	Coronary Artery Disease	—
NCT07762794	Not disclosed	Not yet recruiting	Sponsor	HUMA	—	Vascular Injury; Arterial Injury; Trauma Injury	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Humacyte, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

HUMA — Humacyte Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials